Boehringer Ingelheim Acquires Exclusive License from Sitryx Therapeutics for Preclinical Small Molecule Program February 26, 2026
Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics February 26, 2026
Crystalys Therapeutics Appoints Tim Walbert, Former Horizon Therapeutics CEO, as Independent Board Director February 11, 2026
